SG11201811178UA - Adenoviral vector - Google Patents
Adenoviral vectorInfo
- Publication number
- SG11201811178UA SG11201811178UA SG11201811178UA SG11201811178UA SG11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA
- Authority
- SG
- Singapore
- Prior art keywords
- oxford
- orcrb
- international
- oxfordshire
- roosevelt
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 241000701161 unidentified adenovirus Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 244000028344 Primula vulgaris Species 0.000 abstract 1
- 235000016311 Primula vulgaris Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT omit VIII Hot o III om OH Holm Imo lII ois (10) International Publication Number WO 2017/221031 Al (51) International Patent Classification: C12N 15/86 (2006.01) A61K 39/12 (2006.01) C12N 15/861 (2006.01) A61K 39/02 (2006.01) (21) International Application Number: PCT/GB2017/051851 (22) International Filing Date: 23 June 2017 (23.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1610967.0 23 June 2016 (23.06.2016) GB (71) Applicant: OXFORD UNIVERSITY INNOVATION LIMITED [GB/GB]; Buxton Court, 3 West Way, Botley Oxfordshire OX2 OJB (GB). (72) Inventors: GILBERT, Sarah C; The Jenner Institute Lab- oratories, ORCRB, Roosevelt Drive, Oxford Oxfordshire OX3 7DQ (GB). HILL, Adrian, VS; The Jenner Institute Laboratories, ORCRB, Roosevelt Drive, Oxford Oxford- shire OX3 7DQ (GB). COTTINGHAM, Matthew, G; The Jenner Institute Laboratories, ORCRB, Roosevelt Drive, Oxford Oxfordshire OX3 7DQ (GB). DICKS, Matthew; The Jenner Institute Laboratories, ORCRB, Roosevelt Dri- ye, Oxford Oxfordshire OX3 7DQ (GB). MORRIS, Susan, J; The Jenner Institute Laboratories, ORCRB, Roosevelt Drive, Oxford Oxfordshire OX3 7DQ (GB). DOUGLAS, Alexander; The Jenner Institute Laboratories, ORCRB, Roosevelt Drive, Oxford Oxfordshire OX3 7D (GB). (74) Agent: GILL JENNINGS & EVERY LLP et al.; The Broadgate Tower, 20 Primrose Street, London Greater Lon- don, EC2A 2ES (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: ADENOVIRAL VECTOR (57) : The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector compris- ing the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orfl, E4Orf2 and E4Orf3 coding regions from AdY25. [Continued on next page] W O 20 17 / 22103 1 A WO 2017/221031 Al 0111 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1610967.0A GB2549809C (en) | 2016-06-23 | 2016-06-23 | Vector |
PCT/GB2017/051851 WO2017221031A1 (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811178UA true SG11201811178UA (en) | 2019-01-30 |
Family
ID=56891578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811178UA SG11201811178UA (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Country Status (13)
Country | Link |
---|---|
US (2) | US11306325B2 (en) |
EP (2) | EP3943604A1 (en) |
JP (2) | JP7187451B2 (en) |
KR (1) | KR102205908B1 (en) |
CN (1) | CN109790548B (en) |
AU (1) | AU2017282102B2 (en) |
CA (1) | CA3027686A1 (en) |
DK (1) | DK3475433T3 (en) |
ES (1) | ES2883354T3 (en) |
GB (1) | GB2549809C (en) |
MX (1) | MX2018016074A (en) |
SG (1) | SG11201811178UA (en) |
WO (1) | WO2017221031A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
JP7015551B2 (en) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Exogenous gene expression in therapeutic adenovirus to minimize its impact on viral dynamics |
JP7054527B2 (en) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | High-throughput assay to measure adenovirus replication kinetics |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
BR112020019942A2 (en) * | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | oncolytic adenovirus compositions with enhanced replication properties |
GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
CN109602901B (en) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | Herpes zoster virus vaccine and preparation method and application thereof |
CA3140019A1 (en) * | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
KR20220074917A (en) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | HBV vaccines and methods of treating HBV |
CN113088538A (en) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | Expression vector based on chimpanzee ChAd3 adenovirus and construction method thereof |
CN113088530A (en) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | Expression vector based on chimpanzee ChAd63 adenovirus and construction method thereof |
WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
RU2720614C9 (en) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Immunobiological agent and a method for use thereof for inducing specific immunity against the sars-cov-2 severe acute respiratory syndrome virus (versions) |
CN114845733A (en) * | 2020-08-22 | 2022-08-02 | 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” | Expression vector for resisting SARS-CoV-2 of severe acute respiratory syndrome virus |
WO2022122036A1 (en) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | Immunogen and pharmaceutical composition for sars-cov-2 virus, and use thereof |
CN112552380B (en) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | Immunogen of SARS-CoV-2 virus and its application |
CN112831524B (en) * | 2021-02-20 | 2023-06-13 | 苏州相奕生物技术有限公司 | Artificially modified recombinant adenovirus vector, virus packaged by same and application thereof |
CN116103242A (en) * | 2023-01-10 | 2023-05-12 | 潍坊医学院 | ESAT6-CAR-T for targeted treatment of tuberculosis, and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE449105T1 (en) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | CHIMPANZEE ADENOVIRUS VACCINE CARRIAGE |
AU2010209938A1 (en) * | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
CA2851251C (en) * | 2011-10-05 | 2023-09-12 | Genvec, Inc. | Simian (gorilla) adenovirus or adenoviral vectors and methods of use |
GB201318084D0 (en) * | 2013-10-11 | 2013-11-27 | Isis Innovation | Malaria vaccination |
BR112016008806A2 (en) | 2013-11-01 | 2017-10-03 | Pfizer | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS |
GB201413530D0 (en) * | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
-
2016
- 2016-06-23 GB GB1610967.0A patent/GB2549809C/en active Active
-
2017
- 2017-06-23 CA CA3027686A patent/CA3027686A1/en active Pending
- 2017-06-23 JP JP2019520507A patent/JP7187451B2/en active Active
- 2017-06-23 KR KR1020197002318A patent/KR102205908B1/en active IP Right Grant
- 2017-06-23 AU AU2017282102A patent/AU2017282102B2/en active Active
- 2017-06-23 SG SG11201811178UA patent/SG11201811178UA/en unknown
- 2017-06-23 CN CN201780039028.8A patent/CN109790548B/en active Active
- 2017-06-23 EP EP21182840.5A patent/EP3943604A1/en active Pending
- 2017-06-23 DK DK17734440.5T patent/DK3475433T3/en active
- 2017-06-23 US US16/310,281 patent/US11306325B2/en active Active
- 2017-06-23 ES ES17734440T patent/ES2883354T3/en active Active
- 2017-06-23 EP EP17734440.5A patent/EP3475433B9/en active Active
- 2017-06-23 WO PCT/GB2017/051851 patent/WO2017221031A1/en unknown
- 2017-06-23 MX MX2018016074A patent/MX2018016074A/en unknown
-
2022
- 2022-01-28 US US17/587,376 patent/US11970709B2/en active Active
- 2022-08-15 JP JP2022129264A patent/JP7333857B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11306325B2 (en) | 2022-04-19 |
ES2883354T3 (en) | 2021-12-07 |
CA3027686A1 (en) | 2017-12-28 |
CN109790548A (en) | 2019-05-21 |
EP3475433B1 (en) | 2021-07-21 |
KR20190020131A (en) | 2019-02-27 |
WO2017221031A1 (en) | 2017-12-28 |
US20220220507A1 (en) | 2022-07-14 |
EP3475433B9 (en) | 2022-08-24 |
JP2019519252A (en) | 2019-07-11 |
EP3943604A1 (en) | 2022-01-26 |
AU2017282102A1 (en) | 2019-01-03 |
JP7333857B2 (en) | 2023-08-25 |
US20190175716A1 (en) | 2019-06-13 |
GB2549809C (en) | 2022-11-30 |
GB2549809B (en) | 2019-04-03 |
AU2017282102B2 (en) | 2023-03-23 |
JP7187451B2 (en) | 2022-12-12 |
GB201610967D0 (en) | 2016-08-10 |
DK3475433T3 (en) | 2021-08-16 |
MX2018016074A (en) | 2019-09-09 |
EP3475433A1 (en) | 2019-05-01 |
US11970709B2 (en) | 2024-04-30 |
JP2022159418A (en) | 2022-10-17 |
KR102205908B1 (en) | 2021-01-22 |
CN109790548B (en) | 2024-03-22 |
GB2549809A (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811178UA (en) | Adenoviral vector | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201808709VA (en) | T cell receptors | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201808750PA (en) | T cell receptors | |
SG11201407923TA (en) | Liquid optical adhesive compositions | |
SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201408054RA (en) | Pegylated oxm variants | |
SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201911572YA (en) | Adenoviral vectors | |
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
SG11201806538WA (en) | Engineered antigen presenting cells and uses thereof |